pentamidine has been researched along with Leishmania Infection in 58 studies
Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.
pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| " For Chagas disease, two anti-fungal triazoles are now in clinical trial." | 4.88 | Management of trypanosomiasis and leishmaniasis. ( Barrett, MP; Croft, SL, 2012) |
| "Pentamidine has a long history in the treatment of human African trypanosomiasis (HAT) and leishmaniasis." | 3.74 | Pentamidine dosage: a base/salt confusion. ( Dorlo, TP; Kager, PA, 2008) |
| "Metronidazole has been claimed in several earlier reports to be active in human cases of leishmaniasis and trypanosomiasis." | 3.66 | Inefficacy of metronidazole in experimental infections of Leishmania donovani, L. mexicana, and Trypanosoma brucei brucei. ( Keithly, JS; Langreth, SG, 1983) |
| "Bioanalytical method development and validation for the quantification of antileishmanial drugs are pivotal to support clinical trials and provide the data necessary to conduct pharmacokinetic (PK) analysis." | 3.01 | Bioanalytical methods for pharmacokinetic studies of antileishmanial drugs. ( Beijnen, JH; Dorlo, TPC; Roseboom, IC; Rosing, H, 2023) |
| "Leishmaniasis is an infectious disease responsible for a huge rate of morbidity and mortality in humans." | 3.01 | A Systematic Review of Drug-Carrying Nanosystems Used in the Treatment of Leishmaniasis. ( Carneiro, SP; Registre, C; Rubio, KTS; Santos, ODH; Soares, RDOA, 2023) |
| "Leishmaniasis is a parasitic neglected tropical disease caused by various species of Leishmania parasite." | 2.72 | Recent advancements in anti-leishmanial research: Synthetic strategies and structural activity relationships. ( Bhatia, R; Gupta, O; Monga, V; Pradhan, T, 2021) |
| "In the search for new treatments against Chagas disease and leishmaniasis, several studies have shown that hybrid molecules display high antiprotozoal activity and this emerging strategy is quite promising in the field of new drug discovery and development." | 2.58 | Hybrid Molecules: Promising Compounds for the Development of New Treatments Against Leishmaniasis and Chagas Disease. ( Cardona-G, W; Herrera-R, A; Yepes, AF, 2018) |
| "Fluconazole treatment for 6 weeks speeds up the already-rapid cure rate of cutaneous disease due to Leishmania major." | 2.42 | Current treatment approaches to leishmaniasis. ( Berman, J, 2003) |
| "Leishmaniasis is a parasitic disease caused by a hemoflagellate, Leishmania spp." | 2.42 | Challenges and new discoveries in the treatment of leishmaniasis. ( Singh, S; Sivakumar, R, 2004) |
| " In spite of the high number of reported cases of HIV-related VL, the treatment of choice, the best dosage and the duration of therapy appear not to be properly established." | 2.41 | Leishmaniases and HIV/AIDS co-infections: review of common features and management experiences. ( Ali, A, 2002) |
| " Drug combination studies, performed on L." | 1.37 | In vitro activity of nicotinamide/antileishmanial drug combinations. ( Ait-Oudhia, K; Garcia, D; Gazanion, E; Ouaissi, A; Oury, B; Sereno, D; Seveno, M; Vergnes, B, 2011) |
| "Pentamidine was bound to the polymer by ionic interaction." | 1.30 | Physicochemical characteristics of pentamidine-loaded polymethacrylate nanoparticles: implication in the intracellular drug release in Leishmania major infected mice. ( Astier, A; Boulard, Y; Deniau, M; Durand, R; Fernandez, C; Fusaï, T; Paul, M; Rivollet, D, 1998) |
| "Antileishmanial chemotherapy is hampered by the location of parasites within lysosomal vacuoles of the macrophages which restricts the bioavailability of many potential antileishmanial compounds." | 1.29 | [In vitro study of leishmanicidal agents with drug carriers]. ( Astier, A; Bories, C; Couvreur, P; Deniau, M; Durand, R; Houin, R; Paul, M, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 24 (41.38) | 18.7374 |
| 1990's | 3 (5.17) | 18.2507 |
| 2000's | 12 (20.69) | 29.6817 |
| 2010's | 15 (25.86) | 24.3611 |
| 2020's | 4 (6.90) | 2.80 |
| Authors | Studies |
|---|---|
| Pandey, S | 1 |
| Suryawanshi, SN | 1 |
| Goyal, N | 1 |
| Gupta, S | 1 |
| Roldos, V | 1 |
| Nakayama, H | 1 |
| Rolón, M | 1 |
| Montero-Torres, A | 1 |
| Trucco, F | 1 |
| Torres, S | 1 |
| Vega, C | 1 |
| Marrero-Ponce, Y | 1 |
| Heguaburu, V | 1 |
| Yaluff, G | 1 |
| Gómez-Barrio, A | 1 |
| Sanabria, L | 1 |
| Ferreira, ME | 1 |
| Rojas de Arias, A | 1 |
| Pandolfi, E | 1 |
| Patil, V | 1 |
| Guerrant, W | 1 |
| Chen, PC | 1 |
| Gryder, B | 1 |
| Benicewicz, DB | 1 |
| Khan, SI | 1 |
| Tekwani, BL | 1 |
| Oyelere, AK | 1 |
| dos Santos, MS | 1 |
| Oliveira, ML | 1 |
| Bernardino, AM | 1 |
| de Léo, RM | 1 |
| Amaral, VF | 1 |
| de Carvalho, FT | 1 |
| Leon, LL | 3 |
| Canto-Cavalheiro, MM | 1 |
| Passalacqua, TG | 1 |
| Torres, FA | 1 |
| Nogueira, CT | 1 |
| de Almeida, L | 1 |
| Del Cistia, ML | 1 |
| dos Santos, MB | 1 |
| Dutra, LA | 1 |
| Bolzani, VS | 1 |
| Regasini, LO | 1 |
| Graminha, MA | 1 |
| Marchetto, R | 1 |
| Zottis, A | 1 |
| Saad, SM | 1 |
| Ghouri, N | 1 |
| Perveen, S | 1 |
| Khan, KM | 1 |
| Choudhary, MI | 1 |
| do Espírito Santo, RD | 1 |
| Velásquez, ÁMA | 1 |
| Passianoto, LVG | 1 |
| Sepulveda, AAL | 1 |
| da Costa Clementino, L | 1 |
| Assis, RP | 1 |
| Baviera, AM | 1 |
| Kalaba, P | 1 |
| Dos Santos, FN | 1 |
| Éberlin, MN | 1 |
| da Silva, GVJ | 1 |
| Zehl, M | 1 |
| Lubec, G | 1 |
| Graminha, MAS | 1 |
| González, ERP | 1 |
| Gupta, O | 1 |
| Pradhan, T | 1 |
| Bhatia, R | 1 |
| Monga, V | 1 |
| Roseboom, IC | 1 |
| Rosing, H | 1 |
| Beijnen, JH | 1 |
| Dorlo, TPC | 1 |
| Registre, C | 1 |
| Soares, RDOA | 1 |
| Rubio, KTS | 1 |
| Santos, ODH | 1 |
| Carneiro, SP | 1 |
| Valentim-Silva, JR | 1 |
| Macedo, SRA | 1 |
| de Barros, NB | 1 |
| Dos Santos Ferreira, A | 1 |
| da Silva, JHM | 1 |
| de Figueiredo Nicolete, LD | 1 |
| Nicolete, R | 1 |
| Ortega, V | 1 |
| Giorgio, S | 1 |
| de Paula, E | 1 |
| Cardona-G, W | 1 |
| Yepes, AF | 1 |
| Herrera-R, A | 1 |
| Valle, IV | 1 |
| Machado, ME | 1 |
| Araújo, CDCB | 1 |
| da Cunha-Junior, EF | 1 |
| da Silva Pacheco, J | 1 |
| Torres-Santos, EC | 1 |
| da Silva, LCRP | 1 |
| Cabral, LM | 1 |
| do Carmo, FA | 1 |
| Sathler, PC | 1 |
| de Albuquerque Melo, GM | 1 |
| Silva, MC | 1 |
| Guimarães, TP | 1 |
| Pinheiro, KM | 1 |
| da Matta, CB | 1 |
| de Queiroz, AC | 1 |
| Pivatto, M | 1 |
| Bolzani, Vda S | 1 |
| Alexandre-Moreira, MS | 1 |
| Viegas, C | 1 |
| Fagundes-Silva, GA | 1 |
| Romero, GA | 1 |
| Cupolillo, E | 1 |
| Yamashita, EP | 1 |
| Gomes-Silva, A | 1 |
| Guerra, JA | 1 |
| Da-Cruz, AM | 1 |
| Sbaraglini, ML | 1 |
| Vanrell, MC | 1 |
| Bellera, CL | 1 |
| Benaim, G | 1 |
| Carrillo, C | 1 |
| Talevi, A | 1 |
| Romano, PS | 1 |
| Dorlo, TP | 1 |
| Kager, PA | 1 |
| Genovese, G | 1 |
| Tedone, L | 1 |
| Hamann, MT | 1 |
| Morabito, M | 1 |
| Rosquete, LI | 1 |
| Cabrera-Serra, MG | 1 |
| Piñero, JE | 1 |
| Martín-Rodríguez, P | 1 |
| Fernández-Pérez, L | 1 |
| Luis, JG | 1 |
| McNaughton-Smith, G | 1 |
| Abad-Grillo, T | 1 |
| Gazanion, E | 1 |
| Vergnes, B | 1 |
| Seveno, M | 1 |
| Garcia, D | 1 |
| Oury, B | 1 |
| Ait-Oudhia, K | 1 |
| Ouaissi, A | 1 |
| Sereno, D | 1 |
| COLLIER, HO | 1 |
| LOURIE, EM | 1 |
| Singh, N | 1 |
| Kumar, M | 1 |
| Singh, RK | 1 |
| Barrett, MP | 1 |
| Croft, SL | 1 |
| Werbovetz, KA | 1 |
| Genestra, M | 1 |
| Echevarria, A | 2 |
| Cysne-Finkelstein, L | 2 |
| Vignólio-Alves, L | 1 |
| Ali, A | 1 |
| SILVA, YP | 1 |
| AZULAY, RD | 1 |
| VIVAS, A | 1 |
| AZULAY, E | 1 |
| WILLIAMSON, J | 1 |
| Berman, J | 1 |
| BOIX BARRIOS, J | 1 |
| SANCHO PASQUAU, V | 1 |
| QUILIS MORA, J | 1 |
| SOTO, JF | 1 |
| Singh, S | 1 |
| Sivakumar, R | 1 |
| Temporal, RM | 1 |
| Silva-Gonçalves, AJ | 1 |
| Genestra, MS | 1 |
| Roscoe, M | 1 |
| Werbovetz, K | 1 |
| HAZARIKA, AN | 1 |
| Thakur, CP | 1 |
| Belehu, A | 2 |
| Naafs, B | 2 |
| Berman, JD | 2 |
| Wyler, DJ | 1 |
| Keithly, JS | 1 |
| Langreth, SG | 1 |
| Low-A-Chee, RM | 1 |
| Rose, P | 1 |
| Ridley, DS | 1 |
| Bachrach, U | 1 |
| Abu-Elheiga, L | 1 |
| Schnur, LF | 1 |
| Zaar, K | 1 |
| Wunderlich, F | 1 |
| Deniau, M | 2 |
| Durand, R | 2 |
| Bories, C | 1 |
| Paul, M | 2 |
| Astier, A | 2 |
| Couvreur, P | 1 |
| Houin, R | 1 |
| Boulard, Y | 1 |
| Fusaï, T | 1 |
| Fernandez, C | 1 |
| Rivollet, D | 1 |
| Smit, AM | 1 |
| van der Kaay, HJ | 1 |
| Briggaman, RA | 1 |
| Bryceson, A | 1 |
| Kern, P | 1 |
| Sharma, VK | 1 |
| Kaur, S | 1 |
| Mahajan, RC | 1 |
| Joshi, K | 1 |
| Kumar, B | 1 |
| Singh, NK | 1 |
| Agrawal, SK | 1 |
| Jha, TK | 1 |
| Mukherjee, T | 1 |
| Ray, M | 1 |
| Bhaduri, A | 1 |
| Bourée, P | 1 |
| Anciaux, ML | 1 |
| Taugourdeau, P | 1 |
| Pradinaud, R | 1 |
| Pearson, RD | 1 |
| Hewlett, EL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia.[NCT00471705] | Phase 3 | 437 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Complete Clinical response: Initial cure plus the absence of recurrences or mucosal lesions for 6 months after the end of treatment.~Note: nitial cure: Complete re-epithelialization of all ulcers and complete disappearance of the induration up to 3 months after the end of treatment." (NCT00471705)
Timeframe: Until 6 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 85 |
| Glucantime® | 103 |
| Thermotherapy | 86 |
At least 50% increase in lesion size at the end of treatment, absence of clinical response at 6 weeks, or any sign of lesion activity 3 months after the end of treatment (NCT00471705)
Timeframe: Until 3 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 34 |
| Glucantime® | 14 |
| Thermotherapy | 42 |
Reactivation of the lesion at the original site after cure or mucosal compromise during follow-up. (NCT00471705)
Timeframe: Until 6 months post-treatment
| Intervention | Participants (Number) |
|---|---|
| Miltefosine | 3 |
| Glucantime® | 4 |
| Thermotherapy | 6 |
17 reviews available for pentamidine and Leishmania Infection
| Article | Year |
|---|---|
Recent advancements in anti-leishmanial research: Synthetic strategies and structural activity relationships.
Topics: Animals; Cell Line, Tumor; Heterocyclic Compounds; Humans; Leishmania; Leishmaniasis; Molecular Stru | 2021 |
Bioanalytical methods for pharmacokinetic studies of antileishmanial drugs.
Topics: Amphotericin B; Antiprotozoal Agents; Humans; Leishmaniasis; Pentamidine | 2023 |
A Systematic Review of Drug-Carrying Nanosystems Used in the Treatment of Leishmaniasis.
Topics: Antiprotozoal Agents; Humans; Leishmaniasis; Paromomycin; Pentamidine; Pharmaceutical Preparations | 2023 |
Liposomal formulations in the pharmacological treatment of leishmaniasis: a review.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Compounding; Drug Delivery Systems; Drug Liberat | 2017 |
Hybrid Molecules: Promising Compounds for the Development of New Treatments Against Leishmaniasis and Chagas Disease.
Topics: Antiprotozoal Agents; Chagas Disease; Chalcone; Humans; Hydrazones; Leishmaniasis; Pentamidine; Quin | 2018 |
Neglected Tropical Protozoan Diseases: Drug Repositioning as a Rational Option.
Topics: Antiprotozoal Agents; Chagas Disease; Drug Repositioning; Humans; Leishmaniasis; Neglected Diseases; | 2016 |
Leishmaniasis: current status of available drugs and new potential drug targets.
Topics: Aminoquinolines; Amphotericin B; Antigens, Protozoan; Antimony Sodium Gluconate; Antiprotozoal Agent | 2012 |
Management of trypanosomiasis and leishmaniasis.
Topics: Administration, Oral; Africa; Amphotericin B; Antiprotozoal Agents; Benzamides; Boron Compounds; Cha | 2012 |
Promising therapeutic targets for antileishmanial drugs.
Topics: Animals; Antiprotozoal Agents; Chalcones; Clinical Trials as Topic; Drug Design; Drug Evaluation, Pr | 2002 |
Leishmaniases and HIV/AIDS co-infections: review of common features and management experiences.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Anti-HIV Agents; Antiprotozoal Agents; Antire | 2002 |
Current treatment approaches to leishmaniasis.
Topics: Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Clinical Trials as Topic; Fluconazo | 2003 |
Challenges and new discoveries in the treatment of leishmaniasis.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Therapy, Combination; Humans; Leishmania; Leishm | 2004 |
Leishmaniasis: early diagnosis is key.
Topics: Animals; Antimony; Antiprotozoal Agents; Diagnosis, Differential; Early Diagnosis; Humans; Leishmani | 2005 |
Diamidines as antitrypanosomal, antileishmanial and antimalarial agents.
Topics: Animals; Antimalarials; Antiprotozoal Agents; Benzamidines; Chagas Disease; Clinical Trials as Topic | 2006 |
The aromatic diamidines.
Topics: Amidines; Animals; Dermatomycoses; Humans; Leishmaniasis; Mice; Mycoses; Pentamidine; Pneumonia, Pne | 1977 |
[Use of pentamidine in protozoan diseases].
Topics: Humans; Leishmaniasis; Pentamidine; Pneumonia, Pneumocystis; Protozoan Infections; Trypanosomiasis, | 1990 |
Pentamidine for the treatment of Pneumocystis carinii pneumonia and other protozoal diseases.
Topics: Amidines; Humans; Leishmaniasis; Pentamidine; Pneumonia, Pneumocystis; Protozoan Infections; Trypano | 1985 |
41 other studies available for pentamidine and Leishmania Infection
| Article | Year |
|---|---|
Chemotherapy of leishmaniasis. Part V: Synthesis and in vitro bioevaluation of novel pyridinone derivatives.
Topics: Antiprotozoal Agents; Drug Evaluation, Preclinical; Humans; Leishmaniasis; Pyridones | 2007 |
Activity of a hydroxybibenzyl bryophyte constituent against Leishmania spp. and Trypanosoma cruzi: in silico, in vitro and in vivo activity studies.
Topics: Animals; Antiprotozoal Agents; Bibenzyls; Cattle; Cell Line; Computational Biology; Extracellular Sp | 2008 |
Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group.
Topics: Antimalarials; Antiprotozoal Agents; Histone Deacetylase Inhibitors; Histone Deacetylases; Leishmani | 2010 |
Synthesis and antileishmanial evaluation of 1-aryl-4-(4,5-dihydro-1H-imidazol-2-yl)-1H-pyrazole derivatives.
Topics: Animals; Antiprotozoal Agents; Imidazoles; Leishmania; Leishmaniasis; Mice; Pyrazoles; Structure-Act | 2011 |
The 2',4'-dihydroxychalcone could be explored to develop new inhibitors against the glycerol-3-phosphate dehydrogenase from Leishmania species.
Topics: Animals; Antiprotozoal Agents; Chalcones; Glycerolphosphate Dehydrogenase; Leishmania; Leishmaniasis | 2015 |
4-Arylamino-6-nitroquinazolines: Synthesis and their activities against neglected disease leishmaniasis.
Topics: Antiprotozoal Agents; Dose-Response Relationship, Drug; Humans; Leishmania major; Leishmaniasis; Mol | 2016 |
N, N', N″-trisubstituted guanidines: Synthesis, characterization and evaluation of their leishmanicidal activity.
Topics: Animals; Antiprotozoal Agents; Dose-Response Relationship, Drug; Female; Guanidines; Leishmania; Lei | 2019 |
Antileishmanial drugs activate inflammatory signaling pathways via toll-like receptors (docking approach) from Leishmania amazonensis-infected macrophages.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Cell Line; Inflammation; Leishmania; Leishmaniasis; M | 2020 |
Oral pentamidine-loaded poly(d,l-lactic-co-glycolic) acid nanoparticles: an alternative approach for leishmaniasis treatment.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Biological Availability; Disease Models, Animal | 2019 |
Leishmanicidal activity of the crude extract, fractions and major piperidine alkaloids from the flowers of Senna spectabilis.
Topics: Antiparasitic Agents; Flowers; Ketones; Leishmania major; Leishmaniasis; Life Cycle Stages; Medicine | 2014 |
Leishmania (Viannia) naiffi: rare enough to be neglected?
Topics: Adolescent; Adult; Antimony Sodium Gluconate; Antiprotozoal Agents; Brazil; Demography; Electrophore | 2015 |
Pentamidine dosage: a base/salt confusion.
Topics: Antiprotozoal Agents; Guidelines as Topic; Humans; Leishmaniasis; Pentamidine; Trypanocidal Agents; | 2008 |
The Mediterranean red alga Asparagopsis: a source of compounds against Leishmania.
Topics: Amphotericin B; Inhibitory Concentration 50; Italy; Leishmania; Leishmaniasis; Mediterranean Sea; Pe | 2009 |
Synthesis and in vitro antiprotozoal evaluation of substituted phenalenone analogues.
Topics: Antiprotozoal Agents; Cell Line, Tumor; Humans; Leishmaniasis; Pentamidine; Phenalenes; Trypanosoma | 2010 |
In vitro activity of nicotinamide/antileishmanial drug combinations.
Topics: Amphotericin B; Antimony; Antiprotozoal Agents; Cell Line; DNA Fragmentation; Drug Combinations; Dru | 2011 |
The action in vitro of diamidines and other compounds on Leishmania donovani.
Topics: Humans; In Vitro Techniques; Leishmania donovani; Leishmaniasis; Pentamidine | 1946 |
Effect of amidine derivatives on nitric oxide production by Leishmania amazonensis promastigotes and axenic amastigotes.
Topics: Amidines; Animals; Leishmania mexicana; Leishmaniasis; Molecular Structure; Nitric Oxide; Pentamidin | 2003 |
[Lomidine in the treatment of tegumentary leishmaniasis].
Topics: Humans; Leishmaniasis; Pentamidine | 1952 |
[Case of cutaneous leishmaniasis simulating syphilis (face) and frambesia (lower extremities) successfully treated with a diamidine].
Topics: Amidines; Face; Humans; Leishmaniasis; Leishmaniasis, Cutaneous; Lower Extremity; Pentamidine; Syphi | 1953 |
Prophylactic inactivity of pentamidine in experimental leishmaniasis.
Topics: Leishmaniasis; Pentamidine | 1955 |
[Treatment of kala-azar with diamidine].
Topics: Amidines; Humans; Leishmaniasis; Leishmaniasis, Visceral; Pentamidine | 1950 |
Amidine derivatives and Leishmania amazonensis: an evaluation of the effect of nitric oxide (NO) production on the parasite-macrophage interaction.
Topics: Amidines; Animals; Humans; Leishmania; Leishmaniasis; Macrophages; Nitric Oxide; Nitric Oxide Syntha | 2005 |
Treatment of kala-azar with pentamidine isothionate; a study of 55 cases.
Topics: Humans; Leishmaniasis; Leishmaniasis, Visceral; Pentamidine | 1949 |
Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis).
Topics: Adolescent; Adult; Antimony Sodium Gluconate; Child; Child, Preschool; Disease Outbreaks; Female; Hu | 1984 |
Diabetes mellitus associated with pentamidine mesylate.
Topics: Adult; Amidines; Diabetes Mellitus; Female; Humans; Leishmaniasis; Pentamidine; Terminology as Topic | 1982 |
An in vitro model for investigation of chemotherapeutic agents in leishmaniasis.
Topics: Amidines; Amphotericin B; Antimony Sodium Gluconate; Gluconates; Humans; Leishmaniasis; Macrophages; | 1980 |
In vitro susceptibility of antimony-resistant Leishmania to alternative drugs.
Topics: Amphotericin B; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antimony; Formycins; Humans; Imi | 1982 |
Inefficacy of metronidazole in experimental infections of Leishmania donovani, L. mexicana, and Trypanosoma brucei brucei.
Topics: Animals; Antimony Sodium Gluconate; Cricetinae; Leishmaniasis; Leishmaniasis, Visceral; Mesocricetus | 1983 |
An outbreak of cutaneous leishmaniasis in Guyana: epidemiology, clinical and laboratory aspects.
Topics: Adolescent; Adult; Child; Disease Outbreaks; Female; Guyana; Humans; Leishmaniasis; Lymphatic System | 1983 |
Leishmania tropica major: effect of paromomycin and pentamidine on polyamine levels in the skin of normal and infected mice.
Topics: Adenosylmethionine Decarboxylase; Amidines; Animals; Drug Evaluation, Preclinical; Leishmaniasis; Ma | 1983 |
Electron microscopical studies on cutaneous leishmaniasis in Ethiopia. I. The diffuse form and its treatment with pentamidine.
Topics: Adult; Amidines; Female; Humans; Leishmania; Leishmaniasis; Male; Microscopy, Electron; Pentamidine; | 1982 |
[In vitro study of leishmanicidal agents with drug carriers].
Topics: Cell Line; Cyanoacrylates; Drug Carriers; Drug Evaluation; Humans; Leishmaniasis; Pentamidine; Polym | 1993 |
Physicochemical characteristics of pentamidine-loaded polymethacrylate nanoparticles: implication in the intracellular drug release in Leishmania major infected mice.
Topics: Animals; Female; Humans; Kupffer Cells; Leishmania major; Leishmaniasis; Mice; Mice, Inbred BALB C; | 1998 |
Cutaneous leishmaniasis [proceedings].
Topics: Antimony; Antimony Sodium Gluconate; Humans; Leishmaniasis; Leishmaniasis, Mucocutaneous; Metronidaz | 1977 |
Cutaneous leishmaniasis.
Topics: Amphotericin B; Antimony; Humans; Leishmania; Leishmaniasis; Pentamidine; Skin | 1976 |
Disseminated cutaneous leishmaniasis.
Topics: Antimony Sodium Gluconate; Drug Therapy, Combination; Humans; Leishmaniasis; Male; Middle Aged; Pent | 1989 |
Persistent hyperglycaemia requiring insulin therapy following the use of pentamidine in the treatment of kala-azar.
Topics: Adult; Child; Humans; Hyperglycemia; Insulin; Leishmaniasis; Male; Pentamidine | 1989 |
Aspartate transcarbamylase from Leishmania donovani. A discrete, nonregulatory enzyme as a potential chemotherapeutic site.
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Ammonia); Chro | 1988 |
[Methylglucamine antimoniate and sodium stibogluconate in the treatment of leishmaniasis. Study of 16 cases].
Topics: Adolescent; Adult; Antimony; Antimony Sodium Gluconate; Child; Child, Preschool; Female; Gluconates; | 1985 |
[Tegumentary leishmaniasis in French Guiana].
Topics: French Guiana; Humans; Leishmaniasis; Pentamidine | 1988 |
Pentamidine-induced diabetes mellitus.
Topics: Amidines; Diabetes Mellitus; Humans; Leishmaniasis; Pentamidine | 1985 |